2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

3078 : Assessment of post-treatment anti-drug antibodies to caplacizumab in clinical trial participants with immune-mediated thrombotic thrombocytopenic purpura: Updates from mayari

Shruti Chaturvedi Jr, MBBS, MS, Paul Coppo, MD2, Flora Peyvandi3, Brendy Van Bustel4, Gabriela Marcheva, PharmD5, Paul Brinkkoetter, MD6, Sriya Gunawardena, MD7, Marie-Paule Bouche8, Laura Sargentini9
1 Department of Medicine, Johns Hopkins University, Baltimore, United States
2 Centre de Référence des Microangiopathies Thrombotiques, Service d’Hématologie, Assistance Publique–Hôpitaux de Paris (AP-HP) and Sorbonne Université, Paris, France
3 Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
4 Sanofi, Ghent, Belgium
5 Sanofi, Cambridge, Massachusetts, United States
6 7Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
7 Sanofi, Cambridge, Massachusetts, United States
8 Sanofi, Ghent, Belgium
9 Sanofi, Ghent, Belgium

Background

Treatment approaches for immune thrombotic thrombocytopenic purpura (iTTP) include therapeutic plasma exchange (TPE) and immunosuppressive therapy (IST), together with caplacizumab (a bivalent anti–von Willebrand Factor humanized single variable domain compound). As part of its clinical development program, caplacizumab was administered with TPE and IST to patients with iTTP in the Phase 2 TITAN trial, Phase 3 HERCULES and Post-HERCULES trials, and a Phase 2/3 trial in Japanese patients (referred to hereafter as the Japanese trial). Caplacizumab demonstrated efficacy, as evidenced by reduced time to platelet count response and time to platelet count normalization, with an acceptable safety. In all four trials, drug-induced treatment emergent anti-drug antibodies (TE-ADAs) were assessed. TPE can complicate measurement of anti-drug antibodies by potential transfer of pre-existing ADAs (pre-Abs) from donor plasma or by dilution of TE-ADAs. The open label, single arm, multicenter, phase 3 MAYARI trial evaluated use of caplacizumab and IST without concurrent first line TPE in adults with iTTP. This therapeutic approach will allow for a better evaluation of the immunogenicity profile of caplacizumab, by eliminating the potential interference of TPE.

Objectives

To report the incidence of ADA using a simplified immunogenicity strategy, which allows to have a clear view on the treatment emergent (TE) ADA and pre-Ab status of a patients receiving caplacizumab without TPE.

Methods

Immunogenicity data from patients with iTTP receiving caplacizumab in 4 clinical trials (NCT01151423 [TITAN], NCT02553317 [HERCULES], NCT02878603 [Post HERCULES], NCT04074187 [Japanese trial]) has been published previously (Van Butsel et al, RPTH 2024; doi.org/10.1016/j.rpth.2024.102620); data from the completed MAYARI (NCT05468320) trial are added. All samples were initially assessed using an ADA assay, which detects both pre-Abs and TE-ADA; all positive samples were subsequently characterized using secondary assays i.e. the modified ADA assay (mADA). The latter was used to differentiate pre-Abs from caplacizumab treatment-ADAs in patients receiving TPE. A neutralizing epitope characterization assay (NECA) and functional neutralizing antibody (NAb) assay both assessed the presence of ADAs with caplacizumab neutralizing potential via different mechanisms. The MAYARI study solely used the ADA in combination with the NECA assay; NECA and NAb assay data were not available for TITAN. The impact of ADAs on efficacy and safety was also evaluated.

Results

Among 278 patients across 5 studies, baseline pre-Ab incidence varied widely: 17.1% (6/35; TITAN), 22% (11/50; MAYARI), 26.7% (20/75; Post-HERCULES), 38.1% (8/21; Japanese study), and 56.7% (55/97; HERCULES). TE-ADA prevalence was generally low across studies: 3.1% (HERCULES), 6% (MAYARI), 8.% (TITAN), 10.7% (Post-HERCULES), and 14.3% (Japanese study). Fewer than 15% of participants in any trial had TE-ADA with neutralizing potential (NECA: 2.7-14.3%, NAb 0.0-12.0%). NECA incidence in MAYARI was 6% (3/50). The presence of pre-Abs, TE-ADAs, and TE neutralizing antibodies did not impact treatment efficacy (platelet normalization, recurrence) or safety across all studies

 

Conclusion

For most clinical trials, a complex immunogenicity assay strategy was required to define the pre-Ab and TE-ADA status of patients with iTTP treated with caplacizumab and IST plus TPE. Within the MAYARI trial, a simplified assay strategy (i.e.  omission of the mADA assay) allowed a more straight forward and clear interpretation of the ADA data and subsequently revealed a similar outcome compared to the complex immunogenicity strategy applied in previous studies. Despite a wide range of pre-Abs observed across studies, there was no apparent impact of pre-Ab, TE-ADA or TE neutralizing antibody on caplacizumab efficacy and no serious adverse events were reported in subjects with TE-ADA.

This study was funded by Sanofi. The authors thank Hannah Clarke PharmD (Sanofi) for publication coordination. The authors had full editorial control of the abstract and provided their final approval of all content.
Gabriela Marcheva, PharmD: Sanofi - Current Employment